Senior Scientific, a subsidiary of nanotechnology developer Manhattan Scientifics, has formed a research collaboration with Weill Cornell Medicine to explore the use of molecularly targeted nanoparticles for detecting and diagnosing prostate cancer.
The company said it will provide its magnetic relaxometry technology to Weill Cornell. The research agreement is the third for the vendor; University of Michigan Medical School is researching the technology's application for breast cancer, while MD Anderson Cancer Center is investigating its use in ovarian cancer.
